Pfizer reported Q3 2026 revenue of $16.58 billion and adjusted EPS of $0.87, surpassing analyst expectations. The company's non-COVID product portfolio grew 7% operationally, with new and acquired products up 32%, offsetting declines in COVID-related sales. Pfizer raised its full-year 2026 revenue guidance to $62–$64 billion and adjusted EPS to $2.95–$3.05, supported by cost savings and a strong dividend yield of 5.73%. The positive outlook suggests potential share price appreciation toward the mid-$30 range.
Pfizer shares are trading at USD 30.70 on Pluang, showing a 2.32% gain in the last day. The stock offers a dividend yield of 5.73%, with a market cap of $170.99 billion as of Nov 05, 2026 03:21 WIB.
Moderna's stock rose 5% ahead of its earnings report, continuing a strong 685% gain this year, driven by its mRNA vaccine focus and oncology pipeline. Pfizer's shares fell 0.8% despite beating Q3 revenue estimates and raising its 2026 guidance, as CO...
UPS paid $5.4 billion in dividends in 2025, surpassing its free cash flow of $4.8 billion, signaling potential payout risks. Similar concerns apply to Pfizer, AGNC Investment, and Kraft Heinz, where dividends outpace earnings or cash flow, threatenin...
Pfizer reported third-quarter earnings that exceeded analyst expectations, with adjusted earnings per share of 87 cents versus the expected 73 cents, and revenue of $16.58 billion beating the $15.87 billion forecast. The company raised its full-year ...
